An UPLC-MS/MS Method for Determination of Osimertinib in Rat Plasma: Application to Investigating the Effect of Ginsenoside Rg3 on the Pharmacokinetics of Osimertinib

Osimertinib is a novel oral, potent, and irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) for treatment of advanced T790M mutation-positive advanced non-small cell lung cancer, which is commonly combined with ginsenoside Rg3 in clinic to enhance the efficacy and min...

Descripción completa

Detalles Bibliográficos
Autores principales: Ying, Zhenzhen, Wei, Jingyao, Liu, Ruijuan, Zhao, Fang, Yu, Yifang, Tian, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785372/
https://www.ncbi.nlm.nih.gov/pubmed/33456471
http://dx.doi.org/10.1155/2020/8814214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785372/
https://www.ncbi.nlm.nih.gov/pubmed/33456471
http://dx.doi.org/10.1155/2020/8814214

Ejemplares similares